John Oyler, Chief Executive Officer at BeiGene, Ltd. (BGNE), sold 32,250 shares at $231.04 ($7.5M) on 2024-10-08, disclosed to the SEC on 2024-10-10.
Scheduled sale ($7.5M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $229.25 | 2,535 | $581K | 7.8% |
| 2 | $229.25 | 1,565 | $359K | 4.8% |
| 3 | $229.25 | 1,565 | $359K | 4.8% |
| 4 | $229.25 | 2,535 | $581K | 7.8% |
| 5 | $230.05 | 1,747 | $402K | 5.4% |
| 6 | $230.05 | 2,827 |
| $650K |
| 8.7% |
| 7 | $230.05 | 2,827 | $650K | 8.7% |
| 8 | $230.05 | 1,747 | $402K | 5.4% |
| 9 | $231.04 | 371 | $86K | 1.1% |
| 10 | $231.04 | 371 | $86K | 1.1% |
| 11 | $231.05 | 229 | $53K | 0.7% |
| 12 | $231.05 | 229 | $53K | 0.7% |
| 13 | $233.00 | 38 | $9K | 0.1% |
| 14 | $233.00 | 62 | $14K | 0.2% |
| 15 | $234.27 | 428 | $100K | 1.3% |
| 16 | $234.27 | 694 | $163K | 2.2% |
| 17 | $234.27 | 694 | $163K | 2.2% |
| 18 | $234.27 | 428 | $100K | 1.3% |
| 19 | $235.41 | 2,059 | $485K | 6.5% |
| 20 | $235.41 | 1,272 | $299K | 4.0% |
| 21 | $235.41 | 1,272 | $299K | 4.0% |
| 22 | $235.41 | 2,059 | $485K | 6.5% |
| 23 | $236.37 | 1,452 | $343K | 4.6% |
| 24 | $236.37 | 896 | $212K | 2.8% |
| 25 | $236.37 | 896 | $212K | 2.8% |
| 26 | $236.37 | 1,452 | $343K | 4.6% |
| Total | $232.21 avg | 32,250 | $7.5M | 100% |
| Filing → |
| ONC | SELL | 2026-07-17 | $89.4M | — | Filing → |
| ONC | SELL | 2026-07-17 | $20.2M | — | Filing → |
| ONC | SELL | 2026-07-14 | $44.6M | — | Filing → |